Blood Transfusion Diagnostics Market Report 2025

This Blood Transfusion Diagnostics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The blood transfusion diagnostics market size has grown rapidly in recent years. It will grow from $4.42 billion in 2024 to $4.96 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increasing blood transfusions, emerging pathogens, aging population, increasing demand for rapid blood transfusion diagnostics, rising prevalence of chronic diseases, increased blood demand.

The blood transfusion diagnostics market size is expected to see strong growth in the next few years. It will grow to $6.43 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to rising demand for precision medicine, growing investment in blood transfusion infrastructure, growing demand for molecular blood transfusions, emerging infectious diseases, blood safety concerns. Major trends in the forecast period include advancements in diagnostics, point-of-care testing, automation and robotics, nucleic acid testing (NAT), digital integration, expanded pathogen panels, advanced testing technologies.

The demand for blood transfusion diagnostics is on the rise, fueled by the increasing number of surgeries performed annually. These diagnostics are crucial in screening donated blood before transfusion to patients, preventing potential infectious diseases. With an estimated 310 million surgeries conducted each year, the necessity for blood transfusion diagnostics is growing in tandem with these procedures.

Blood-related diseases are contributing significantly to the expansion of the blood transfusion diagnostics market. Conditions like anemias, leukemia, and clotting disorders necessitate precise diagnostics for early detection and safe management. The prevalence of these diseases is evident, with statistics from January 2023 showing approximately 59,610 new cases and 23,710 deaths from leukemia, while acute myeloid leukemia (AML) accounted for around 20,380 new cases. This prevalence drives the need for improved diagnostics to ensure optimal patient care.

The inclination toward nucleic acid amplification testing (NAT) for blood safety and efficiency is growing due to its accuracy in detecting pathogens like bacteria and viruses. This testing method, detecting specific nucleic acids of pathogens in blood, tissue, or urine, offers high sensitivity and early identification of infectious diseases. XCRP Diagnostic Inc. and Luminex Corporations' agreement for the Xtreme Chain Reaction Nucleic Acid Amplification Technology exemplifies the industry's focus on advancing diagnostic capabilities through strategic partnerships.

Leading companies in the blood transfusion diagnostics market are developing advanced technologies, including innovations in transfusion methods, to enhance the accuracy of blood typing, improve patient safety, minimize the risk of transfusion-transmitted infections, and optimize the overall transfusion process. Innovations in transfusion technology encompass advancements in the methods, devices, and processes utilized in blood transfusion. For example, in June 2024, Innobiochips Co. Ltd., a biotechnology company based in France, introduced Omnys, a significant innovation in blood grouping and testing. This cutting-edge diagnostic platform is designed to deliver rapid and precise blood typing, compatibility testing, and pathogen detection. It utilizes advanced biomarker identification and automation to streamline the transfusion process, ensuring that blood products are accurately matched to patients for safe transfusions.

Major companies operating in the blood transfusion diagnostics market include BAG Health Care GmbH, Grifols S.A., Bio-Rad LaboratoriesInc., Abbott Laboratories, Immucor Inc., Ortho Clinical Diagnostics, DiaSorin S.p.A, Siemens Healthineers, Thermo Fisher Scientific Inc., Beckman Coulter Inc., Novartis AG, F. Hoffmann-La Roche Ltd., bioMerieux, Diagast SAS, Fujirebio, Biokit S.A., QuidelOrtho Corporation, Danaher Corporation, Becton Dickinson and Company, Quotient Biodiagnostics, Sekisui Diagnostics, Sysmex Corporation, Werfen S.A.

Blood transfusion diagnostics play a crucial role in conducting tests before the transfer of blood between donors and recipients, encompassing assessments like blood grouping and disease screening.

These diagnostics are primarily categorized into instruments and kits, along with reagents and other ancillary tools. Blood transfusion diagnostic kits are instrumental in collecting and safely transfusing blood, utilizing technologies like western blot, ELISA, nucleic acid amplification, fluorescence assays, and rapid testing. These technologies are employed across diverse applications, specifically in blood grouping and disease screening procedures. End-users of blood transfusion diagnostics span various sectors, including hospitals, diagnostic laboratories, blood banks, and companies engaged in plasma fractionation. These entities rely on these diagnostic tools to ensure the safe and accurate transfer of blood components between donors and recipients.

The blood transfusion diagnostics market research report is one of a series of new reports that provides blood transfusion diagnostics market statistics, including blood transfusion diagnostics industry global market size, regional shares, competitors with a blood transfusion diagnostics market share, detailed blood transfusion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the blood transfusion diagnostics industry. This blood transfusion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the blood transfusion diagnostics market in 2024. Western Europe was the second-largest region in the blood transfusion diagnostics industry. The regions covered in the blood transfusion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood transfusion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The blood transfusion diagnostics market consists of revenues earned by entities by providing installation and maintenance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood transfusion diagnostics market also includes sales of blood transfusion diagnostics devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.